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Notable cases
tions involve gastrointestinal symptoms. Bone-marrow
and thrombocytopenia are also reported rarely.
The second- and third-generation bisphosphonates
cantly more potent than their first-generation predeces
nate, clodronate and tiludronate). They inhibit bone r
osteoclastic inhibition, through selective concentration
face of the active osteoclast and the bone-resorption ere
ass
sevH  we present five cases of osteonecrosis of the jawociated with bisphosphonate use. In North America,eral preliminary reports have been published of unu-
sual cases of avascular necrosis of the jaw in patients using second-
and third-generation nitrogen-containing bisphosphonates.1-4
These included pamidronate, alendronate, risedronate and
zoledronic acid.2,3
In Australia, bisphosphonates have been available for several
years and are commonly prescribed for a range of conditions,
including osteoporosis, Paget’s disease, multiple myeloma,5,6 hyper-
calcaemia of malignancy, and bone metastases of malignancies such
as breast and prostate cancer. An estimated 200 000 patients in





 at the inter-
surface. The
specific mechanism of this inhibition is unknown, but there is
evidence for several actions, including inhibition of osteoclast
development from precursor cells, increase in osteoclast apoptosis,7
stimulation of osteoclast inhibitory factor, reduction of osteoclast
activity, and down-regulation of matrix metalloproteinases. The
resulting reduction in osteoclastic activity reduces bone resorption,
supporting the use of bisphosphonates for the above indications.
However, osteoclastic function is part of the cycle of bone
turnover; osteocytes have a life span of about 150 days, after which
osteoclasts resorb the mineral matrix of bone and release bone
morphogenetic protein and insulin-like growth factors, which in
turn induce local stem cells to differentiate into osteoblasts and
form new bone. This cycle is critical to maintaining bone stocks and
bone viability. If osteoclastic function is too severely impaired, dead
and dying osteocytes are not replaced, and the capillary network in
the bone is not maintained, resulting in avascular bone necrosis.
Dental disease and denture-wearing are ubiquitous. Studies
involving larger patient numbers have shown that nearly 80% of
cases were initiated by tooth removal.3 Patients who have been
using potent bisphosphonates for more than 6 months appear to be
at highest risk.2 Other apparent risk factors are residual multiple
myeloma or other malignancy, hypoproteinaemia, renal impairment
from disease or drugs, and chemotherapy.
1 Necrosis of the maxilla in a 57-year-old man receiving 
pamidronate for multiple myeloma
The oral cavity showing exposed necrotic maxillary bone and a 
large oro-antral communication.
Computed tomography showing significant bone destruction in the 
right maxilla (outlined).
Clinical records
In 2003, five patients presented to the Oral and Maxillofacial 
Surgery Unit at Royal Adelaide Hospital, South Australia, with 
painful exposed bone in the maxilla, or both the maxilla and 
mandible (Box 1 and Box 2).
All patients were receiving either pamidronate (Aredia [Novartis]) or 
alendronate (Fosamax [Merck Sharp & Dohme]). Pamidronate was 
being given intravenously monthly at a dose of 60 mg (one patient) 
or 90 mg (three patients). The patient taking alendronate received a 
daily oral dose of 40 mg. Duration of bisphosphonate therapy was 
6 months to 6 years. 
Associated risk factors for the development of avascular necrosis 
included renal impairment in one patient and hypoproteinaemia in 
another.
Initial management of these patients comprised surgical 
debridement of the exposed bone. Histopathological assessment 
of surgical specimens showed no histological evidence of 
myelomatous deposits or Paget’s disease from the affected sites in 
the jaws in any of the patients. None had exposed bone elsewhere 
in the body. 
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NOTABLE CASESAlthough a definite cause-and-effect relationship is yet to be
established, the association between bisphosphonate therapy and
osteonecrosis of the jaw appears strong.2-4,8-10 The incidence of the
potential complication appears low. In South Australia in 2003,
about 14 000 patients received prescriptions for the potent second-
and third-generation nitrogen-containing bisphosphonates, with
about 10% having intravenous administration. Our five patients
probably represented all cases of the complication, as our Depart-
ment is the only oral and maxillofacial surgery service in SA and
receives referrals from around the state.8,9 Checking with colleagues
and related hospital services has not revealed further cases in SA,
but we are aware of other cases in all states of Australia. Indeed, the
Adverse Drug Reactions Advisory Committee recently reported
another nine cases.10
At present, there is no effective treatment for the condition.
Patients are usually referred to oral and maxillofacial surgeons, but
surgical intervention is difficult as it often exposes further bone,
and, as bisphosphonates affect the whole skeleton, locating viable
bone margins may be impossible. Furthermore, removal of painful
teeth, while initially alleviating pain, also further exposes bone,
causing more pain. Covering exposed bone with tissue flaps has
been found ineffective because of the development of fistulae
around the flaps and possible complete dehiscence (Box 1).
Compounding the problem, some patients must continue with
bisphosphonate therapy and/or other chemotherapies to control
hypercalcaemia. Hyperbaric oxygen therapy is not useful in
bisphosphonate-induced necrosis, and antibiotics are indicated
only to treat secondary infection.
Because of the lack of effective treatment for the condition,
second- and third-generation bisphosphonates should be used only
when benefits clearly outweigh risks. When intravenous or high-
dose oral bisphosphonates are considered appropriate, referral for
full dental assessment and treatment before the start of therapy
should be considered. Once bisphosphonate therapy has begun,
there should be regular clinical monitoring of oral health. Avoiding
tooth removal and dental implants, non-surgical control of perio-
dontal disease, and use of soft liners on dentures also seem prudent.
In addition, major debridement surgeries should be avoided if at all
possible.
In established cases, the primary goals are palliation and
control of osteomyelitis. In most cases, progression has been
controlled with long-term or intermittent courses of dicloxacillin
or cephalexin (to treat any secondary infection), chlorhexidine
mouthwash (Savacol), and periodic minor debridement of soft-
textured sequestrating bone and wound irrigation.
The rapid expansion of indications for bisphosphonates has
resulted in their widespread use across many medical disciplines,
including endocrinology, rheumatology, medical oncology, hae-
matology and general practice. Most medical practitioners are
unaware of this serious and potentially permanent complication.
Before prescribing bisphosphonates, medical practitioners
should analyse the risks versus benefits for the individual patient,
consider alternative drugs, and obtain informed consent after
discussing this potential adverse reaction. We also encourage
vigilant surveillance of patients who are using a bisphosphonate.
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[indication] Other medications Treatment Outcome
57, M Painful exposed 





(90 mg IV monthly 
for 6 years) 
[multiple myeloma]
Dexamethasone, methotrexate, 










64, M Ulcer in right hard 





(90 mg IV monthly 
















(40 mg orally daily 






primary flap closure, 
bisphosphonate ceased 
Resolution





(90 mg IV monthly 
for 18 months) 
[Paget’s disease]







84, F Non-healing 






(60 mg IV monthly 
for 6 months) 
[Paget’s disease]
Diltiazem, simvastatin, ferrous 
sulfate, aspirin, bendrofluazide
Wide intraoral resection 
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Summary
• Five patients presented to the Royal Adelaide Hospital, South 
Australia, in 2003 with painful exposed bone in the maxilla, or 
both the maxilla and mandible.
• All had been receiving potent second- or third-generation 
bisphosphonate therapy — monthly intravenous pamidronate in 
four cases and daily oral alendronate in the other.
• These cases are among the earliest reported occurrences of this 
condition in association with bisphosphonate therapy in 
Australia.
• The condition presented after tooth extraction in four cases and 
denture pressure in the other.
• Osteonecrosis continued for more than a year in three patients 
despite treatment.MJA • Volume 182 Number 8 • 18 April 2005 415
